Top 5 Medical Device VC Funds & Investors in Iceland (June 2026)

Portfolio highlights

• Numan — Convenient care, tailored to you. Offering treatments for weight loss, diagnostics, erectile dysfunction, hair loss, and more.
• Nord Security — Nord Security is the leader in the field of online privacy and security. Our security tools have earned praise from respected experts and tech outlets.
• Steel City Interactive — Steel City Interactive develops gaming.

Portfolio highlights

• Chimerix — Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.
• Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
• TScan Therapeutics — Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien velit, aliquet eget commodo nec, auctor a sapien. Nam eu neque vulputate diam rhoncus faucibus. Curabitur quis varius libero.

Portfolio highlights

• Optise — Optise is an AI-powered website insights tool for B2B businesses.
• MyDello — Get instant quotes for all transportation modes. Enter a new era of freight forwarding with the MyDello logistics platform. Sign up for free
• Euler —

Portfolio highlights

• HorseDay — HorseDay is a mobile application to track horse activities.
• Spectaflow — Spectaflow is a SaaS solution for accommodations businesses focused on improving housekeeping and maintenance workflows
• PayAnalytics — PayAnalytics, a leading pay equity and workforce analytics solution, aids companies in closing pay gaps and fostering workplace equity. Ensure compliance with pay transparency regulations, assess wage disparities, and analyze workforce demographics conveniently.

Portfolio highlights

• Sidekick Health — Our mission is to develop and deliver effective personalized digital therapeutics that prevent suffering and add millions of quality life years to people around the world. Our multi-chronic digital care platform allows us to scale the production of clinical treatments across major chronic diseases.
• Nuage Therapeutics — Nuage Therapeutics is a pharmaceutical company which utilizes chemical biology and biomolecular condensation to develop selective drugs that target proteins with disordered regions for challenging indications to improve patient’s life. The focus of the medication is to enhance selective inhibitors of intrinsically disordered proteins involved inchallenging indications in order to meet unmet medical needs.
• Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.